Lang, W., Huang, B., Zhang, G., Deng, L., Lu, H., Lu, M., Pan, Y. (2026). Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China. Scientific Reports. https://doi.org/10.1038/s41598-026-39026-0